OBI Pharma Inc (浩鼎生技) has signed an agreement with Odeon Therapeutics (Hong Kong) Ltd (康騰浩諾香港生物科技) to give it the rights to two of its experimental drugs, OBI-833 and OBI-999, in China, OBI said on Tuesday.
OBI would receive US$200 million for the licensing of the cancer drugs, which includes US$12 million in newly issued Odeon shares as a signing payment, and US$188 million as development and commercialization milestone payments, the Taipei-based company said in a regulatory filing.
The drug developer would also receive double-digit percentage royalties on Odeon’s net sales of the two drugs after they are approved in China, it said.
Photo: Chen Yung-chi, Taipei Times
OBI granted Odeon exclusive rights to further develop, register and commercialize OBI-999 and OBI-833, it said, adding that the deal also includes Hong Kong and Macau.
Odeon would be responsible for all development costs, as well as subsequent regulatory and commercialization costs, it added.
The Ministry of Economic Affairs’ Investment Commission has approved the deal, OBI said.
As China’s cancer treatment market has great potential for growth, OBI and Odeon are planning to press ahead with the research and sale of the two drugs, aiming to share the commercial benefits, the filing said.
OBI-833 and OBI-999 are experimental drugs targeting Globo H, a tumor antigen that has been detected in up to 15 different cancers and has been reported to play an important role in tumor progression.
OBI-833 is a therapeutic cancer vaccine consisting of a synthetic Globo H antigen, while OBI-999 is a novel antibody drug conjugate using a Globo H antibody to target cancer cells with high Globo H expression.
“Odeon looks forward to working closely with OBI to bring these new treatment options to patients in China,” OBI chief executive officer Tim Xiao (肖汀) said in a statement.
OBI-999 has completed phase 1 trials in the US, showing excellent safety and pharmacokinetics, while OBI-333 also demonstrated great potential as an immune-oncology therapeutic vaccine, Xiao said.
OBI said that it gained local approval to conduct phase 2 clinical trial for OBI-333, expecting primary endpoint evaluation in 2024.
With this year’s Semicon Taiwan trade show set to kick off on Wednesday, market attention has turned to the mass production of advanced packaging technologies and capacity expansion in Taiwan and the US. With traditional scaling reaching physical limits, heterogeneous integration and packaging technologies have emerged as key solutions. Surging demand for artificial intelligence (AI), high-performance computing (HPC) and high-bandwidth memory (HBM) chips has put technologies such as chip-on-wafer-on-substrate (CoWoS), integrated fan-out (InFO), system on integrated chips (SoIC), 3D IC and fan-out panel-level packaging (FOPLP) at the center of semiconductor innovation, making them a major focus at this year’s trade show, according
DEBUT: The trade show is to feature 17 national pavilions, a new high for the event, including from Canada, Costa Rica, Lithuania, Sweden and Vietnam for the first time The Semicon Taiwan trade show, which opens on Wednesday, is expected to see a new high in the number of exhibitors and visitors from around the world, said its organizer, SEMI, which has described the annual event as the “Olympics of the semiconductor industry.” SEMI, which represents companies in the electronics manufacturing and design supply chain, and touts the annual exhibition as the most influential semiconductor trade show in the world, said more than 1,200 enterprises from 56 countries are to showcase their innovations across more than 4,100 booths, and that the event could attract 100,000 visitors. This year’s event features 17
SEMICONDUCTOR SERVICES: A company executive said that Taiwanese firms must think about how to participate in global supply chains and lift their competitiveness Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said it expects to launch its first multifunctional service center in Pingtung County in the middle of 2027, in a bid to foster a resilient high-tech facility construction ecosystem. TSMC broached the idea of creating a center two or three years ago when it started building new manufacturing capacity in the US and Japan, the company said. The center, dubbed an “ecosystem park,” would assist local manufacturing facility construction partners to upgrade their capabilities and secure more deals from other global chipmakers such as Intel Corp, Micron Technology Inc and Infineon Technologies AG, TSMC said. It
EXPORT GROWTH: The AI boom has shortened chip cycles to just one year, putting pressure on chipmakers to accelerate development and expand packaging capacity Developing a localized supply chain for advanced packaging equipment is critical for keeping pace with customers’ increasingly shrinking time-to-market cycles for new artificial intelligence (AI) chips, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) said yesterday. Spurred on by the AI revolution, customers are accelerating product upgrades to nearly every year, compared with the two to three-year development cadence in the past, TSMC vice president of advanced packaging technology and service Jun He (何軍) said at a 3D IC Global Summit organized by SEMI in Taipei. These shortened cycles put heavy pressure on chipmakers, as the entire process — from chip design to mass
RSS